Coalition for Metabolic Health Launches Congressional Briefing Series on Nutrition, Chronic Disease, and GLP-1s
Summary
The Coalition for Metabolic Health held its first Capitol Hill briefing on June 24, co-sponsored by Rep. Lloyd Smucker and Rep. Sharice Davids. The panel examined how nutrition can address chronic disease and reduce healthcare costs, with a focus on nutrition and health in the era of GLP-1 medications. The briefing brought together members of Congress, physicians, researchers, policy experts, and individuals with lived experience of chronic disease.
Source
Key quotes
· 1 pulledRep. Sharice Davids delivered opening remarks highlighting the importance of addressing chronic disease through nutrition.
You might also wanna read
Coalition for Metabolic Health Launches with $50 Million to Address America's Chronic Disease Crisis
The Coalition for Metabolic Health (CMH) has launched with $50 million in seed funding from the Baszucki family to address America's metabol

National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
America's Health Crisis and the New Dietary Guidelines: Restoring Real Food for National Health
The article discusses America's health crisis driven by highly processed foods, highlighting alarming statistics: 50% of Americans have pred
Research Suggests Heart Disease, Kidney Disease and Type 2 Diabetes May Be One Condition Treatable with GLP-1 Drugs
The article discusses the emerging medical concept of "CKM syndrome" (cardiometabolic kidney syndrome), which suggests that heart disease, k
New Dietary Guidelines for Americans Emphasize Whole Foods to Address Health Crisis
The article discusses the new Dietary Guidelines for Americans, which emphasize whole, nutrient-dense, naturally occurring foods as the foun
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w

Comments
Sign in to join the conversation.
No comments yet. Be the first.